Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myelomonocytic, Chronic 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2Leukemia 2Hodgkin Disease 2Hematologic Neoplasms 2Uveal Melanoma 1Shwachman-Diamond Syndrome 1Sarcoma, Ewing 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Docetaxel 277Prednisone 236enzalutamide 175Leuprolide 172Radiotherapy 164Abiraterone Acetate 153Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 78abiraterone 75gallium 68 PSMA-11 74Specimen Handling 67Gonadotropin-Releasing Hormone 58darolutamide 56Radiation 56Triptorelin Pamoate 53cabazitaxel 49Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × treosulfan × Clear all
NCT00427999 2016-11-21

INV342

Novartis

Phase 2 Completed
67 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡